Amarin Corporation plc (AMRN) — 0.9098 (-0.0102)
Key Metrics & Ratings
- symbol AMRN
- Rev/Share 0.7895
- Book/Share 1.3544
- PB 0.8934
- Debt/Equity 0.0162
- CurrentRatio 2.6904
- ROIC -0.1149
- MktCap 451360041.0
- FreeCF/Share 0.0222
- PFCF 49.7312
- PE -9.4175
- Debt/Assets 0.0107
- DivYield 0
- ROE -0.0912
- Rating A
- Score 4.0
- Recommendation Buy
- P/E Score 5.0
- DCF Score 5.0
- P/B Score 4.0
- D/E Score 3.0
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | AMRN | JP Morgan | -- | Underweight | -- | -- | Nov. 20, 2023 |
News
Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference
Published: May 06, 2024 by: GlobeNewsWire
Sentiment: Neutral
DUBLIN, Ireland and BRIDGEWATER, N.J., May 06, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced that Patrick Holt, Amarin's president and chief executive officer, is scheduled to participate in fireside chat at the 2024 H.C. Wainwright 2nd Annual BioConnect Investor Conference.
Read More
Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year?
Published: May 03, 2024 by: Zacks Investment Research
Sentiment: Positive
Here is how Amarin (AMRN) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.
Read More
Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024
Published: April 15, 2024 by: GlobeNewsWire
Sentiment: Neutral
DUBLIN, Ireland and BRIDGEWATER, N.J., April 15, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Patrick Holt, President & CEO, and members of Amarin's senior management team to discuss its first quarter 2024 results followed by Q&A on Wednesday, May 1st, 2024, at 8:00 a.m. ET.
Read More
Amarin (AMRN) Up 7% on Intellectual Property Wins in Europe
Published: April 04, 2024 by: Zacks Investment Research
Sentiment: Positive
Amarin (AMRN) secures a new patent for Vazkepa in Europe, which extends its exclusivity for eight more years. It achieves success in defending another patent on the drug against third parties.
Read More
Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe
Published: April 03, 2024 by: GlobeNewsWire
Sentiment: Neutral
Company's IP Protection for VAZKEPA® in Europe Now Extended Into 2039 Company's IP Protection for VAZKEPA® in Europe Now Extended Into 2039
Read More
Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology's (ACC) Annual Scientific Session & Expo
Published: March 25, 2024 by: GlobeNewsWire
Sentiment: Neutral
-- Subgroup Analyses from REDUCE-IT ® and Mechanistic Data on Icosapent Ethyl(IPE)/Eicosapentaenoic Acid (EPA) Featured at the Meeting -- DUBLIN, Ireland and BRIDGEWATER, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that additional patient subgroup analyses from the landmark REDUCE-IT outcomes trial and mechanistic data on icosapent ethyl (IPE)/eicosapentaenoic acid (EPA) will be presented at the American College of Cardiology's Annual Scientific Session & Expo, April 6 – 8, 2024 in Atlanta, GA.
Read More
Amarin Chairman & CEO Issue Letter to Shareholders
Published: January 22, 2024 by: GlobeNewsWire
Sentiment: Neutral
DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that the Company's Chairman of the Board, Odysseas Kostas, M.D., and President & CEO, Patrick Holt, issued the following letter to Amarin shareholders:
Read More
Are Medical Stocks Lagging Amarin (AMRN) This Year?
Published: January 12, 2024 by: Zacks Investment Research
Sentiment: Negative
Here is how Amarin (AMRN) and Arcutis Biotherapeutics, Inc. (ARQT) have performed compared to their sector so far this year.
Read More
Amarin (AMRN) Stock Rises on Stellar Q4 Preliminary Results
Published: January 11, 2024 by: Zacks Investment Research
Sentiment: Positive
Amarin (AMRN) issues encouraging preliminary results for the fourth quarter and full-year 2023. The company also plans to initiate a share repurchase program of up to $50 million.
Read More
Why Amarin Stock Skyrocketed Today
Published: January 10, 2024 by: The Motley Fool
Sentiment: Positive
Amarin announced better-than-expected fourth-quarter results on Wednesday. The biopharmaceuticals company also announced a $50 million share repurchase program and guidance on capital allocation for 2024.
Read More
Amarin stock soars on preliminary 4Q revenue guidance, share buyback plan
Published: January 10, 2024 by: Proactive Investors
Sentiment: Positive
Amarin Corporation rose by more than a quarter on Wednesday after the drugmaker reported preliminary fourth-quarter revenues well ahead of analysts' expectations. In a business update ahead of its presentation to a J.P.
Read More
Amarin Provides Preliminary Fourth Quarter 2023 Selected Financials and Outlines Key Priorities For 2024
Published: January 10, 2024 by: GlobeNewsWire
Sentiment: Neutral
-- Reported Unaudited Total Revenues of Between $72 Million - $74 Million in the Fourth Quarter of 2023 -- -- Company Ends 2023 with a Cash Position of $321 Million and Delivered Full-Year Positive Cash Flow of ~$10 Million --
Read More
Amarin to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Published: December 11, 2023 by: GlobeNewsWire
Sentiment: Neutral
DUBLIN, Ireland and BRIDGEWATER, N.J., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced its participation in the 42nd Annual JP Morgan Healthcare Conference. Amarin's president and chief executive officer, Patrick Holt, is scheduled to present at the conference on January 10, 2024.
Read More
What Makes Amarin (AMRN) a New Buy Stock
Published: December 05, 2023 by: Zacks Investment Research
Sentiment: Positive
Amarin (AMRN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
Sarissa Capital Believes Amarin Stock Is Meaningfully Undervalued and Has Increased Its Ownership
Published: December 04, 2023 by: Business Wire
Sentiment: Neutral
GREENWICH, Conn.--(BUSINESS WIRE)--Sarissa Capital Management LP (“Sarissa”) today issued the following statement regarding Amarin Corporation plc (NASDAQ: AMRN): Sarissa believes Amarin's stock is significantly undervalued. We continue to believe in both the tremendous value of Vascepa/Vazkepa to cardiovascular patients worldwide and the market opportunity. We are very upset that the stock has remained low. We expect that over time that value will be reflected in the stock price. We hope that.
Read More
Soleno Therapeutics: Impressive Data, But Never Forget Amarin
Published: November 26, 2023 by: Seeking Alpha
Sentiment: Positive
Soleno Therapeutics has seen a surge in stock value after positive data from Phase III trials of its Diazoxide Choline Extended-Release tablet for Prader-Willi Syndrome. The data showed improvements in body composition and hyperphagia-related behaviors in patients treated with the tablet. Soleno Therapeutics faces potential challenges in protecting its intellectual property for the formulation of the drug.
Read More
New REDUCE-IT® Analyses Show VASCEPA® (icosapent ethyl) Associated with 29 Percent Relative Risk Reduction Compared with Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at Baseline
Published: November 12, 2023 by: GlobeNewsWire
Sentiment: Neutral
-- Analysis Also Found IPE Was Associated with a 41% Reduction in Total Events Compared with Placebo -- -- Subgroup Almost Exclusively Comprised of Patients with Established Cardiovascular Disease --
Read More
About Amarin Corporation plc (AMRN)
- IPO Date 1993-04-01
- Website https://www.amarincorp.com
- Industry Biotechnology
- CEO Mr. Patrick J. Holt
- Employees 275